Cerecin Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.74M
- Investors
-
13
Cerecin General Information
Description
Developer of therapeutics technology designed to treat memory impairment and other neurodegenerative diseases. The company offers lipid science to explore the potential therapeutic benefits of medium-chain triglycerides, which are designed to induce ketosis and improve mitochondrial metabolism, and develops novel evidence-based alternatives that help people, pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, enabling clinicians to have access to brain health-focused products and therapies to treat diseases of the brain.
Contact Information
Website
www.cerecin.comCorporate Office
- 11101 West 120th Avenue
- Suite 230
- Broomfield, CO 80021
- United States
Corporate Office
- 11101 West 120th Avenue
- Suite 230
- Broomfield, CO 80021
- United States
Cerecin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC | 17-Jun-2024 | $3.74M | Completed | Clinical Trials - Phase 3 | ||
| 13. Later Stage VC (Series B2) | 02-Aug-2022 | Completed | Clinical Trials - Phase 2 | |||
| 12. Later Stage VC (Series A2) | 14-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 11. Secondary Transaction - Private | 01-Jun-2021 | Completed | Clinical Trials - Phase 1 | |||
| 10. Later Stage VC (Series 2) | 01-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC | 05-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series F) | 26-Mar-2018 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series E) | 21-Jan-2014 | Completed | Clinical Trials - Phase 1 | |||
| 6. Debt - General | 24-May-2012 | $8.78M | $81.2M | Completed | Clinical Trials - Phase 1 | |
| 5. Later Stage VC (Series C1) | 21-Dec-2010 | $11M | $72.4M | Completed | Clinical Trials - Phase 1 |
Cerecin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series A2 | ||||||||
| Series 2 | ||||||||
| Series 1 | 11,983,134 | $0.001000 | 8% | $2.93 | $2.93 | 1x | $2.93 | 10.49% |
| Junior Pref | 44,780,778 | $0.001000 | 8% | $2.93 | $2.93 | 1x | $2.93 | 39.2% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cerecin Comparisons
Industry
Financing
Details
Cerecin Competitors (30)
One of Cerecin’s 30 competitors is Hummingbird Bioscience, a Venture Capital-Backed company based in Singapore, Singapore.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Hummingbird Bioscience | Venture Capital-Backed | Singapore, Singapore | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| TauRx Pharmaceuticals | Private Equity-Backed | Aberdeen, United Kingdom | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Q Therapeutics | Venture Capital-Backed | Salt Lake City, UT |
Cerecin Patents
Cerecin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024384650-A1 | Formulations of lipid nano emulsions with controlled pharmacokinetic profiles and methods of making and using the same | Pending | 26-Nov-2023 | ||
| EP-4812156-A1 | Formulations of lipid nano emulsions with controlled pharmacokinetic profiles and methods of making and using the same | Pending | 26-Nov-2023 | ||
| WO-2025109567-A1 | Formulations of lipid nano emulsions with controlled pharmacokinetic profiles and methods of making and using the same | Inactive | 26-Nov-2023 | ||
| AU-2024284207-A1 | Compositions of and methods of making ultra-pure tricaprilin | Pending | 09-Jun-2023 | ||
| EP-4724415-A1 | Compositions of and methods of making ultra-pure tricaprilin | Pending | 09-Jun-2023 | A61P19/02 |
Cerecin Signals
Cerecin Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AFW Partners | Venture Capital | Minority | ||
| Arche Investment | Corporate Venture Capital | Minority | ||
| Cheongdam Investment | PE/Buyout | |||
| Hana Financial Group | Holding Company | Minority | ||
| IBK Capital | Investment Bank | Minority |
Cerecin FAQs
-
When was Cerecin founded?
Cerecin was founded in 2000.
-
Where is Cerecin headquartered?
Cerecin is headquartered in Broomfield, CO.
-
What is the size of Cerecin?
Cerecin has 35 total employees.
-
What industry is Cerecin in?
Cerecin’s primary industry is Drug Discovery.
-
Is Cerecin a private or public company?
Cerecin is a Private company.
-
What is Cerecin’s current revenue?
The current revenue for Cerecin is .
-
How much funding has Cerecin raised over time?
Cerecin has raised $317M.
-
Who are Cerecin’s investors?
AFW Partners, Arche Investment, Cheongdam Investment, Hana Financial Group, and IBK Capital are 5 of 13 investors who have invested in Cerecin.
-
Who are Cerecin’s competitors?
Hummingbird Bioscience, Verge Labs, TauRx Pharmaceuticals, Alzheon, and Q Therapeutics are some of the 30 competitors of Cerecin.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process